Market Overview:
Recombinant erythropoietin products are utilized to treat anemia conditions caused due to renal diseases, cancer, HIV/AIDS, and other chronic illnesses. The recombinant erythropoietin stimulates the bone marrow to produce more red blood cells, which help in improvement of oxygen delivery in the body. Major types of recombinant erythropoietin products available in the market are Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and others.

Market Dynamics:
One of the major drivers for the growth of the recombinant erythropoietin market is the increasing prevalence of anemia globally. As per the World Health Organization, around 1.6 billion people suffer from anemia worldwide. Factors such as malnutrition, chronic illnesses, and genetic conditions contribute to rising incidences of anemia. This has augmented the demand for recombinant erythropoietin products for anemia treatment. Additionally, continuous technological advancements in recombinant erythropoietin drug development are also boosting the market growth. For instance, long-acting recombinant erythropoietin products such as Darbepoetin-alfa reduce dosing frequency, providing enhanced patient compliance.

The global Recombinant Erythropoietin Market Share is estimated to be valued at US$ 7.01 Billion in 2023 and is expected to exhibit a CAGR of 2.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

SWOT Analysis
Strength: Recombinant erythropoietin has fewer side effects compared to traditional erythropoietin products due to precise control over molecular structure. It has a longer shelf life than natural erythropoietin and eliminates concerns over blood-borne diseases. It can stimulate red blood cell production in patients undergoing dialysis or cancer chemotherapy.

Weakness: Recombinant erythropoietin is significantly more expensive than traditional erythropoietin therapy. The production process involves the use of mammalian cell lines which increases costs. There are concerns over possible increased risk of adverse cardiovascular events and tumor growth with long term use.

Opportunity: Increasing prevalence of anemia in chronic kidney disease and cancer patients offers significant growth opportunities. Favorable reimbursement policies for recombinant erythropoietin treatment in many countries is boosting demand. New recombinant forms with better safety profiles and longer duration of action can expand the market.

Threats: Patent expiries of major brands are expected to boost biosimilar sales and increase pricing pressure on innovator firms. Stringent regulatory norms may delay product approvals. Outbreaks of infectious diseases affecting production can disrupt supply.

Key Takeaways

The global recombinant erythropoietin market is expected to witness high growth, exhibiting a CAGR of 2.0% over the forecast period, due to increasing prevalence of anemia in chronic kidney disease and cancer patients. North America is expected to dominate the market over the forecast period owing to increasing healthcare spending and growing aging population in the region.

Regional analysis

North America is expected to account for over 35% of the global market share due to rising healthcare expenditures and high diagnosis and treatment rates in the US and Canada. Asia Pacific is expected to grow at the fastest pace during the forecast period due to growing geriatric population, rising awareness about EPO therapies and improving access to healthcare in countries like China and India.

Key players

Key players operating in the recombinant erythropoietin market are Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Roche Holding AG, Novartis AG, Biocon Limited, Teva Pharmaceutical Industries Ltd., LG Chem Ltd., Sandoz International GmbH (a subsidiary of Novartis AG), Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., and 3SBio Inc. Amgen Inc. and Johnson & Johnson are the market leaders with a combined global market share of over 50%.

Read More: https://blogger-veritas.blogspot.com/2023/11/telemedicine-is-fastest-growing-segment_20.html